| Autor: |
Schrenk, Karin G., Weschenfelder, Wolfram, Spiegel, Christian, Agaimy, Abbas, Stöhr, Robert, Hartmann, Arndt, Gaßler, Nikolaus, Drescher, Robert, Freesmeyer, Martin, Malouhi, Amer, Bürckenmeyer, Florian, Aschenbach, René, Teichgräber, Ulf, Kögler, Christine, Vogt, Matthias, Hofmann, Gunther O., Hochhaus, Andreas |
| Předmět: |
|
| Zdroj: |
Journal of Cancer Research & Clinical Oncology; Aug2023, Vol. 149 Issue 9, p5493-5496, 4p |
| Abstrakt: |
With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET-fusion-associated sarcomas. As new targeted therapies are under development, similar treatment options may become available for sarcoma patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink